A new study from researchers at Baylor College of Medicine has uncovered a previously unknown mechanism behind metformin, one of the world’s most widely prescribed treatments for Type 2 Diabetes. The findings, published in Science Advances, suggest the drug’s effectiveness may depend significantly on activity within the brain challenging decades of scientific understanding.
For more than 60 years, metformin has been a cornerstone of diabetes care due to its affordability, safety, and ability to lower blood sugar. Until now, it was believed to work primarily by reducing glucose production in the liver and influencing processes in the gut. The latest research introduces a third pathway, centered in the brain.
Key protein identified in the brain
The study focused on a protein known as Rap1, located in a region of the brain called the ventromedial hypothalamus (VMH). Researchers found that metformin’s ability to lower blood sugar at standard doses depends on its capacity to deactivate this protein.
Using genetically modified mice lacking Rap1 in the VMH, scientists observed that metformin no longer reduced blood sugar levels. Notably, other treatments including insulin and GLP-1–based therapies remained effective, indicating that the mechanism is unique to metformin.
Brain shows heightened sensitivity to the drug
Further experiments revealed that the brain responds to metformin at extremely low doses. When researchers administered small amounts of the drug directly into the brains of diabetic mice, blood sugar levels dropped significantly even at concentrations far below typical oral doses.
The team also identified specific brain cells, known as SF1 neurons, that became active in response to metformin but only when Rap1 was present. In the absence of the protein, the drug had no observable effect on these neurons, confirming Rap1’s role as a critical trigger in the process.
Implications for future diabetes treatment
The discovery could reshape the future of diabetes care. By highlighting the brain as an active participant in blood sugar regulation, the findings open the door to new therapies that target this pathway more directly.
Such treatments could potentially work at lower doses, improving precision and reducing side effects. Researchers also believe the findings may help explain other observed benefits of metformin, including its possible role in slowing aspects of brain aging.
A new chapter for a long-standing drug
Despite its long history, metformin continues to reveal new scientific insights. The identification of a brain-based mechanism underscores how much remains to be understood about even the most established medications.
As researchers continue to explore the Rap1 pathway, the study signals a shift in how scientists approach diabetes treatment moving beyond traditional targets like the liver and gut to include the brain as a central player in metabolic health.
and then